188 related articles for article (PubMed ID: 35683032)
1. Anti-Growth, Anti-Angiogenic, and Pro-Apoptotic Effects by CX-4945, an Inhibitor of Casein Kinase 2, on HuCCT-1 Human Cholangiocarcinoma Cells via Control of Caspase-9/3, DR-4, STAT-3/STAT-5, Mcl-1, eIF-2α, and HIF-1α.
Wang S; Yadav AK; Han JY; Ahn KS; Jang BC
Int J Mol Sci; 2022 Jun; 23(11):. PubMed ID: 35683032
[TBL] [Abstract][Full Text] [Related]
2. The Casein Kinase 2 Inhibitor CX-4945 Promotes Cholangiocarcinoma Cell Death Through PLK1.
Lee DS; Lee S; Kim C; Kim D; Kim KP; Yoo C
Anticancer Res; 2022 Jul; 42(7):3435-3443. PubMed ID: 35790285
[TBL] [Abstract][Full Text] [Related]
3. CX-4945 (Silmitasertib) Induces Cell Death by Impairing Lysosomal Utilization in
Lee DS; Han MW; Kang Y; Kim C; Lee S; Kim KP; Yoo C
Anticancer Res; 2024 May; 44(5):1939-1946. PubMed ID: 38677763
[TBL] [Abstract][Full Text] [Related]
4. Dihydroartemisinin/miR-29b combination therapy increases the pro-apoptotic effect of dihydroartemisinin on cholangiocarcinoma cell lines by regulating Mcl-1 expression.
Hu H; Wang Z; Tan C; Liu X; Zhang H; Li K
Adv Clin Exp Med; 2020 Aug; 29(8):911-919. PubMed ID: 32790250
[TBL] [Abstract][Full Text] [Related]
5. Silmitasertib, a casein kinase 2 inhibitor, induces massive lipid droplet accumulation and nonapoptotic cell death in head and neck cancer cells.
Su YW; Huang WY; Lin HC; Liao PN; Lin CY; Lin XY; Huang SH; Chen YT; Wu PS
J Oral Pathol Med; 2023 Mar; 52(3):245-254. PubMed ID: 36273268
[TBL] [Abstract][Full Text] [Related]
6. Anti-growth and pro-apoptotic effects of dasatinib on human oral cancer cells through multi-targeted mechanisms.
Park NS; Park YK; Yadav AK; Shin YM; Bishop-Bailey D; Choi JS; Park JW; Jang BC
J Cell Mol Med; 2021 Sep; 25(17):8300-8311. PubMed ID: 34318593
[TBL] [Abstract][Full Text] [Related]
7. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy.
Siddiqui-Jain A; Drygin D; Streiner N; Chua P; Pierre F; O'Brien SE; Bliesath J; Omori M; Huser N; Ho C; Proffitt C; Schwaebe MK; Ryckman DM; Rice WG; Anderes K
Cancer Res; 2010 Dec; 70(24):10288-98. PubMed ID: 21159648
[TBL] [Abstract][Full Text] [Related]
8. Protein kinase CK2α is overexpressed in classical hodgkin lymphoma, regulates key signaling pathways, PD-L1 and may represent a new target for therapy.
Ruggeri E; Frezzato F; Mouawad N; Pizzi M; Scarmozzino F; Capasso G; Trimarco V; Quotti Tubi L; Cellini A; Cavarretta CA; Ruocco V; Serafin A; Angotzi F; Danesin N; Manni S; Facco M; Piazza F; Trentin L; Visentin A
Front Immunol; 2024; 15():1393485. PubMed ID: 38807597
[TBL] [Abstract][Full Text] [Related]
9. Apatinib Inhibits Angiogenesis in Intrahepatic Cholangiocarcinoma by Regulating the Vascular Endothelial Growth Factor Receptor-2/Signal Transducer and Activator of Transcription Factor 3/Hypoxia Inducible Factor 1 Subunit Alpha Signaling Axis.
Huang MP; Gu SZ; Huang B; Li GW; Xiong ZP; Tang T; Zeng SN
Pharmacology; 2021; 106(9-10):509-519. PubMed ID: 34412054
[TBL] [Abstract][Full Text] [Related]
10. AZD1208, a Pan-Pim Kinase Inhibitor, Has Anti-Growth Effect on 93T449 Human Liposarcoma Cells via Control of the Expression and Phosphorylation of Pim-3, mTOR, 4EBP-1, S6, STAT-3 and AMPK.
Yadav AK; Kumar V; Bailey DB; Jang BC
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30654529
[TBL] [Abstract][Full Text] [Related]
11. ER stress signaling in ARPE-19 cells after inhibition of protein kinase CK2 by CX-4945.
Intemann J; Saidu NE; Schwind L; Montenarh M
Cell Signal; 2014 Jul; 26(7):1567-75. PubMed ID: 24686080
[TBL] [Abstract][Full Text] [Related]
12. Influence of Casein kinase II inhibitor CX-4945 on BCL6-mediated apoptotic signaling in B-ALL in vitro and in vivo.
Richter A; Sender S; Lenz A; Schwarz R; Hinz B; Knuebel G; Sekora A; Murua Escobar H; Junghanss C; Roolf C
BMC Cancer; 2020 Mar; 20(1):184. PubMed ID: 32131762
[TBL] [Abstract][Full Text] [Related]
13. Phosphoproteomic Landscape of AML Cells Treated with the ATP-Competitive CK2 Inhibitor CX-4945.
Rosales M; Rodríguez-Ulloa A; Besada V; Ramón AC; Pérez GV; Ramos Y; Guirola O; González LJ; Zettl K; Wiśniewski JR; Perera Y; Perea SE
Cells; 2021 Feb; 10(2):. PubMed ID: 33562780
[TBL] [Abstract][Full Text] [Related]
14. Casein kinase 2 inhibitor CX-4945 elicits an anti-Warburg effects through the downregulation of TAp73 and inhibits gastric tumorigenesis.
Tang S; Yuan Y; Liu Z; He Y; Pan D
Biochem Biophys Res Commun; 2020 Oct; 530(4):686-691. PubMed ID: 32771361
[TBL] [Abstract][Full Text] [Related]
15. Role of CK2 inhibitor CX-4945 in anti-cancer combination therapy - potential clinical relevance.
D'Amore C; Borgo C; Sarno S; Salvi M
Cell Oncol (Dordr); 2020 Dec; 43(6):1003-1016. PubMed ID: 33052585
[TBL] [Abstract][Full Text] [Related]
16. 4,5,7-Trisubstituted indeno[1,2-b]indole inhibits CK2 activity in tumor cells equivalent to CX-4945 and shows strong anti-migratory effects.
Birus R; El-Awaad E; Ballentin L; Alchab F; Aichele D; Ettouati L; Götz C; Le Borgne M; Jose J
FEBS Open Bio; 2022 Feb; 12(2):394-411. PubMed ID: 34873879
[TBL] [Abstract][Full Text] [Related]
17. CX-4945 Induces Methuosis in Cholangiocarcinoma Cell Lines by a CK2-Independent Mechanism.
Lertsuwan J; Lertsuwan K; Sawasdichai A; Tasnawijitwong N; Lee KY; Kitchen P; Afford S; Gaston K; Jayaraman PS; Satayavivad J
Cancers (Basel); 2018 Aug; 10(9):. PubMed ID: 30142881
[TBL] [Abstract][Full Text] [Related]
18. Targeting protein kinase CK2 suppresses prosurvival signaling pathways and growth of glioblastoma.
Zheng Y; McFarland BC; Drygin D; Yu H; Bellis SL; Kim H; Bredel M; Benveniste EN
Clin Cancer Res; 2013 Dec; 19(23):6484-94. PubMed ID: 24036851
[TBL] [Abstract][Full Text] [Related]
19. Autophagosome-mediated EGFR down-regulation induced by the CK2 inhibitor enhances the efficacy of EGFR-TKI on EGFR-mutant lung cancer cells with resistance by T790M.
So KS; Kim CH; Rho JK; Kim SY; Choi YJ; Song JS; Kim WS; Choi CM; Chun YJ; Lee JC
PLoS One; 2014; 9(12):e114000. PubMed ID: 25486409
[TBL] [Abstract][Full Text] [Related]
20. Hedgehog signaling between cancer cells and hepatic stellate cells in promoting cholangiocarcinoma.
Kim Y; Kim MO; Shin JS; Park SH; Kim SB; Kim J; Park SC; Han CJ; Ryu JK; Yoon YB; Kim YT
Ann Surg Oncol; 2014 Aug; 21(8):2684-98. PubMed ID: 24682719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
